Concern over the Impact of COVID-19 on Domestic and Overseas Economies
First written in FY2020-Q3. 6 of 15 entries say "Restated". Latest entry: FY2024-Q2.
The whole theme swung hardest in 2020: 112 of 175 companies on the "Worse" side.
35 other companies' latest entry also says "Restated".
- FY2024-Q2RestatedAnnual report
「During the six-month period ended 30 November 2023, economic activity in Japan moved toward normalization following the reclassification of COVID-19 as a Category V infectious disease, and the economy showed a moderate recovery trend.」
Following the reclassification of COVID-19 as a Category V infectious disease, continued normalization of economic activity and a moderate recovery in the economy were indicated. - FY2024-Q1RestatedAnnual report
「During the three-month period ended 31 August 2023, conditions in Japan improved moderately as the legal classification of COVID-19 was changed to a Category V infectious disease.」
After COVID-19 was reclassified as a Category V infectious disease, a moderate recovery in the economy was reconfirmed. However, the disclosure did not state that the impact of the disease had been completely eliminated. - FY2023MitigatedAnnual report
「In Japan during the fiscal year, the spread of COVID-19, which had raged since January 2020, subsided after the eighth wave in January this year. From May of the same year, the disease was reclassified under the Infectious Diseases Control Law as a Category V infectious disease.」
The subsiding spread of infections after the eighth wave and the reclassification as a Category V infectious disease in May 2023 eased some of the restrictions on economic and social activity. - FY2023-Q3MitigatedAnnual report
「After the spread of COVID-19 peaked in the seventh wave in August last year, the eighth wave, which peaked in January this year, has also now subsided. From March, the policy of leaving mask-wearing to individual discretion was introduced, and moves to revitalize social and economic activity have emerged while taking into account infection-control measures in each country.」
As the spread of infections in the eighth wave subsided and policies on mask-wearing changed, efforts to revitalize social and economic activity were reported, indicating that the impact of COVID-19 on economic activity had eased in part from the previous quarter. - FY2023-Q2WorsenedAnnual report
「During the six-month period ended 30 November 2022, the increase in infections during the seventh wave in Japan temporarily subsided after peaking in August, and measures were taken to balance preventing the spread of infection with social and economic activity, including the lifting of entry restrictions on visitors from overseas. However, an increase in infections marking an eighth wave was reported from November.」
After the temporary lull following the seventh wave, an increase in infections marking an eighth wave was reported from November, again heightening uncertainty in the external environment due to COVID-19. - FY2023-Q1WorsenedAnnual report
「Against this backdrop, medical institutions had initially shown signs of recovery from the impact of COVID-19, but the renewed increase in cases placed the healthcare supply system under strain. Some facilities were forced to restrict the number of surgeries and outpatient and inpatient visits, and medical institutions continued to face difficult decisions in response to the prolonged spread of infection.」
The renewed spread of infections put pressure on the medical care delivery system and led to restrictions on the number of surgeries and outpatients and inpatients, further intensifying the impact of COVID-19 on the business environment. - FY2022-Q3WorsenedAnnual report
「During the nine-month period ended in the third quarter, Japan's economy remained in a difficult situation, owing mainly to the impact of COVID-19. A new variant, the Omicron variant, was identified in November 2021, and the number of infections subsequently rose again in a sixth wave, with quasi-emergency measures to prevent the spread of the disease being introduced. As a result, the outlook for personal consumption and corporate earnings remained uncertain.」
The identification of the Omicron variant, the renewed rise in infections during the sixth wave and the introduction of quasi-emergency measures were specifically disclosed, indicating heightened uncertainty about the economic outlook. - FY2022-Q2RestatedAnnual report
「In the healthcare industry in which our Group operates, the number of surgeries and outpatients and inpatients is showing signs of recovery from the decline caused by the spread of COVID-19, but medical institutions continue to face difficult operating conditions.」
Although the number of surgeries and outpatients and inpatients showed signs of recovery, the difficult operating environment for medical institutions continued, it was reconfirmed. - FY2022-Q1RestatedAnnual report
「In the healthcare industry, the number of surgeries and outpatients and inpatients, which had declined due to the spread of COVID-19, is showing signs of recovery, but medical institutions continue to face difficult operating conditions.」
Although the number of surgeries and outpatients and inpatients, which had declined due to the spread of COVID-19, showed signs of recovery, the difficult operating environment for medical institutions continued. - FY2021RestatedAnnual report
「Because the decline in sales of consumables resulting from fewer non-COVID-19 consultations and surgical cases, which affected performance during the period, is also expected to continue into the next period depending on future developments, the associated decline in demand for medical equipment and other effects have been incorporated into the next-period earnings forecasts as factors expected to reduce revenue to a certain extent.」
The decline in consultations and surgical cases and the resulting decrease in consumables sales occurred during the period and were incorporated into the earnings forecasts as factors expected to reduce revenue in the next period as well. - FY2021-Q3RestatedAnnual report
「In the healthcare industry, the number of surgeries and outpatients and inpatients, which had declined due to the spread of COVID-19, is showing slight signs of recovery, but medical institutions continue to face extremely difficult operating conditions.」
Although the number of surgeries and outpatients and inpatients showed slight signs of recovery, medical institutions were still described as facing difficult operating conditions. - FY2021-Q2MitigatedAnnual report
「In the healthcare industry, the number of surgeries and outpatients and inpatients, which had declined due to the spread of COVID-19, is showing signs of recovery, but medical institutions continue to face extremely difficult operating conditions.」
The number of surgeries and outpatients and inpatients, which had declined due to the spread of COVID-19, showed signs of recovery, indicating that some of the impact had eased. However, the difficult operating environment for medical institutions continued. - FY2021-Q1MaterialisedAnnual report
「The number of outpatients at our partner medical institutions generally declined, while the number of surgical, examination and treatment cases also continued to fall. As a result, sales of endoscopic and cardiovascular consumables declined in our core medical equipment sales business. In addition, restrictions on sales activities caused by the COVID-19 pandemic affected other business areas, including general equipment and minimally invasive treatment, with business negotiations for sales of equipment such as various diagnostic devices being delayed or put on hold.」
The impact of COVID-19 continued to be reflected in the first quarter through declines in outpatient numbers and surgical and other cases, lower consumables sales, and delays or cancellations of equipment negotiations. - FY2020MaterialisedAnnual report
「During the period, performance across the Group's business areas was affected. Sales declined mainly in the general equipment and minimally invasive treatment fields due to delays in business negotiations and revisions to purchasing plans, while sales of consumables such as IVE (medical materials for endoscopic procedures) and orthopedic consumables declined as the number of surgical, examination and treatment cases fell.」
The impact of COVID-19 was reflected in actual performance through delays in business negotiations, revisions to purchasing plans, a decline in the number of cases and lower consumables sales. - FY2020-Q3First statedAnnual report
「However, uncertainty about overseas economies surrounding trade issues and fluctuations in financial and capital markets, together with concern about the impact of COVID-19 on domestic and overseas economies, means that the outlook remains uncertain.」
Concerns over the impact of COVID-19 on domestic and overseas economies were disclosed for the first time as a new external-environment risk. The disclosure referred to concerns, not to an actual impact having occurred.